The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

• Introduction
• Scope and Methodology
• Total Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

• Overview
• Introduction to Pathogens
• Demographics of the World
• Anti-Infective Drug Resistance
  • Antibiotic Abuse
  • Antibiotic Use in Agriculture
  • Resistance in Select Populations
  • Children
  • The Elderly
  • Compromised Individuals
  • Measures for Reducing Resistance
  • Antibiotic Cycling
  • Antibiotic Education
  • Screening Hospitalized patients
• HIV Trends
  • Infection Rates
  • HIV and Women
  • Costs and Funding of HIV Treatment
  • Access to HIV/AIDS Treatment
• Manufacturer and Marketer Trends
  • Trends in Partnerships and Alliances
  • Developers Trends
  • Trends in Rx-to-OTC Switches

CHAPTER THREE: ANTIFUNGAL DRUGS

• Overview
• Types of Fungal Infections
  • Superficial
  • Systemic
  • Histoplasmosis
  • Coccidioidomycosis
  • Blastomycosis
  • Fungal Infection Statistics
  • Fungal Infection Risk
• Description of Antifungal Products
  • Systemic Antifungals
  • Allylamines
  • Azoles
  • Polyene Macrolides
  • Systemic Miscellaneous Antifungals
  • Topical Antifungals
  • Allylamines
  • Topical Azoles
  • Topical Polyene Macrolides
  • Topical Miscellaneous Antifungals
• Market Overview
• Total Market Size and Forecast
• Antifungal Market by Product Type
  • Allylamines
  • Azoles
  • Polyene Macrolides
  • Other Antifungals
• Antifungal Market by Geographical Region
• Market Analysis by Treated Condition
• Competitive Analysis

CHAPTER FOUR: ANTIBACTERIAL DRUGS

• Overview
• Classification of Antibacterial Organisms
• Antimicrobial Spectrum
• Bacterial Resistance
• Principles of Anti-bacterial Therapy
  • Infecting Organism
  • Antibiotic Sensitivity Testing
  • Site of Infection
  • Host Defenses and Organ Function
  • Antibiotic Pharmacokinetics
  • Monitoring Therapy
• Combination Therapy and Prophylactic Use
• Bacterial Infection Statistics
• Bacterial Infection Risk
• Description of Antibacterial Products
  • Cephalosporins
  • Macrolides
  • Penicillins
  • Quinolones
  • Sulfonamides
  • Tetracyclines
  • Carbopenems
  • Systemic Miscellaneous Antibiotics
• Market Overview
• Total Market Size and Forecast
• Antibacterial Market by Product Type
• Cephalosporins
• Macrolides
• Penicillins
• Quinolones
• Sulfonamides
• Tetracyclines
• Carbopenems
• Other Products
• Antibacterial Market by Geographical Region
• Market Analysis by Treated Condition
• Competitive Analysis
• Leading Products

CHAPTER FIVE: ANTIVIRAL DRUGS

• Overview: Introduction to Viruses
• Examples of Pathogenic Viruses
• Virus Function and Life History
• Replication in DNA Viruses
• Replication of RNA Viruses
• Replication in Retroviruses
• Host Defenses Against Viruses
• Viral Ploys to Invade Host Cells and Circumvent Host Responses
  • Invasion of Host Cells
  • Subversion of the Immune Response
  • Avoidance of Immune Detection and Attack by Killer Cells
• HIV and AIDS
• Viral Infection Statistics
• Description of Antivirals Products
  • Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors
  • Nucleoside Reverse Transcriptase Inhibitors
  • Combination Nucleoside Reverse Transcriptase Inhibitors
  • Nucleotide Analogue Reverse Transcriptase Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Combination Non-Nucleoside Reverse Transcriptase Inhibitors
  • DNA Polymerase Inhibitors
  • Protease Inhibitors
• Other Antivirals
• Market Overview
• Total Market Size and Forecast
  • Antiviral Market by Product Type
  • Nucleoside Analogs
  • Protease Inhibitors
  • Other Antivirals
  • Antiviral Market by Geographical Region
• Market Analysis by Treated Condition
• Competitive Analysis
• Leading Products

CHAPTER SIX: MARKET SUMMARY

• Total Market Size and Forecast
• Market by Segment

CHAPTER SEVEN: CORPORATE PROFILES

• Introduction
• Abbott Laboratories
• AstraZeneca/MedImmune
• Bayer Schering Pharma AG
• Bristol-Myers Squibb
• Daiichi Sankyo
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson Group
• Merck & Co.
• Novartis
• Pfizer
• Roche
• Schering-Plough Corporation
• Wyeth

APPENDIX: LIST OF MAJOR PROVIDERS

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

• Table 1-1: The Global Market for Anti-Infectives by Product Segment, 2006-2013
• Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2009

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

• Table 2-1: Estimated World Population by Age and Geographical Region, 2009
• Figure 2-1: Estimated World Population by Age and Geographical Region, 2009
• Table 2-2: Worldwide HIV/AIDS Infections
• Table 2-3: Women Living with HIV/AIDS, by Region 1990 to 2007 (Percent)
• Table 2-4: AIDS Resource Needs (US$ billion), 2006-2008
• Table 2-5: Antiretroviral Access for HIV Infected Individuals by Region, 2005*
• Table 2-6: Anti-Infective Drugs in Development by Developer
• Table 2-7: Anti-infectives Ingredients Transferred from Rx-to-OTC

CHAPTER THREE: ANTIFUNGAL DRUGS

• Table 3-1: Estimated World and U.S. Incidence of Fungal Infections
• Figure 3-1: Estimated World and U.S. Incidence of Leading Fungal Infections
• Table 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
• Figure 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
• Table 3-3: Systemic Allylamines
• Table 3-4: Systemic Azoles
• Table 3-5: Systemic Polyene Macrolides
• Table 3-6: Systemic Miscellaneous Antifungals
• Table 3-7: Topical Allylamines
• Table 3-8: Topical Azoles
• Table 3-9: Topical Polyene Macrolides
• Table 3-10: Topical Miscellaneous Antifungals
• Table 3-11: The World Market for Antifungal Drugs 2006-2013
• Figure 3-3: The World Market for Antifungal Drugs 2006-2013
• Table 3-12: Antifungal Drug Market by Type 2006-2013
• Figure 3-4: The World Market for Antifungal Drugs Revenues by Type 2006-2013
• Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2009 and 2013
• Table 3-13: The World Market for Antifungal Drugs Estimated Products Sales by Geographic Region 2006-2013
• Figure 3-6: The World Market for Antifungal Drugs Estimated Product Sales by Geographic Region 2006-2013
• Table 3-14: World Antifungal Market Estimated Products Sales by Infection Type, Sales in Millions, 2009
• Figure 3-7: World Antifungal Market Estimated Distribution of Products Sales by Infection Type, 2009
• Table 3-15: World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
• Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of Leading Suppliers 2006-2009
• Figure 3-9: World Market for Antifungal Drugs Estimated Market Share of Leading Suppliers, 2009
• Table 3-16: World Market for Antifungal Drugs Estimated Sales of Select Products 2006-2009
• Figure 3-10: World Market for Antifungal Drugs Estimated Sales of Select Products 2006-2009

CHAPTER FOUR: ANTIBACTERIAL DRUGS

• Table 4-1: Antibiotics with Difficult Penetration
• Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections
• Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections
• Table 4-3: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
• Figure 4-2: World Population at Risk for Serious Bacterial Infections Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
• Table 4-4: Currently Available Cephalosporin Antibiotics (Type, Brand, and Manufacturer)
• Table 4-5: Currently Available Macrolide Antibiotics (Type, Brand, and Manufacturer)
• Table 4-6: Currently Available Penicillin Antibiotics (Type, Brand, and Manufacturer)
• Table 4-6: Currently Available Penicillin Antibiotics (Type, Brand, and Manufacturer)
• Table 4-7: Currently Available Quinolone Antibiotics (Type, Brand, and Manufacturer)
• Table 4-8: Currently Available Sulfonamide Antibiotics (Type, Brand, and Manufacturer)
• Table 4-9: Currently Available Tetracycline Antibiotics (Type, Brand, and Manufacturer)
• Table 4-10: Currently Available Carbopenems (Type, Brand, and Manufacturer)
• Table 4-11: Currently Available Other Miscellaneous Antibiotics (Type, Brand, and Manufacturer)
• Table 4-12: The World Market for Antibacterial Drugs 2006-2013
• Figure 4-3: The World Market for Antibacterial Drugs 2006-2013
• Table 4-13: Antibacterial Drug Market by Type 2006-2013
• Figure 4-4: The World Market for Antibacterial Drugs Revenues by Type 2006-2013
• Figure 4-5: The World Market for Antibacterial Drugs Revenues by Type 2009 and 2013
• Table 4-14: The World Market for Antibacterial Drugs Estimated Products Sales by Geographic Region 2006-2013
• Figure 4-6: The World Market for Antibacterial Drugs Estimated Product Sales by Geographic Region 2006-2013
• Table 4-17: World Antibacterial Market Estimated Products Sales by Infection Type
• Figure 4-7: World Antibacterial Market Estimated Distribution of Products Sales by Infection Type, 2009
• Table 4-18: World Market for Antibacterial Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
• Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of Leading Suppliers 2006-2009
• Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share of Leading Suppliers, 2009
• Table 4-19: World Market for Antibacterial Drugs Estimated Sales of Select Products 2006-2009
• Figure 4-10: World Market for Antibacterial Drugs Estimated Sales of Top Ten Products 2006-2009

CHAPTER FIVE: ANTIVIRAL DRUGS

• Table 5-1: Host Cell Receptors
• Table 5-2: Estimated World and U.S. Incidence of Viral Infections
• Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections
• Table 5-3: Currently Available Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 5-4: Currently Available Combination Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 5-5: Currently Available Nucleotide Analog Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 5-6: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 5-7: Currently Available Combination Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
• Table 5-8: Currently Available DNA Polymerase Inhibitors (Type, Brand, and Manufacturer)
• Table 5-9: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
• Table 5-10: Currently Available Miscellaneous Antivirals (Type, Brand, and Manufacturer)
• Table 5-11: The World Market for Antiviral Drugs 2006-2013
• Figure 5-2: The World Market for Antiviral Drugs 2006-2013
• Table 5-12: Antiviral Drug Market by Type 2006-2013
• Figure 5-3: The World Market for Antiviral Drugs Revenues by Type 2006-2013
• Figure 5-4: The World Market for Antiviral Drugs Revenues by Type 2009 and 2013
• Table 5-13: The World Market for Antiviral Drugs Estimated Products Sales by Geographic Region 2006-2013
• Figure 5-5: The World Market for Antiviral Drugs Estimated Product Sales by Geographic Region 2006-2013
• Table 5-14: World Antiviral Market Estimated Products Sales by Infection Type
• Figure 5-6: World Antiviral Market Estimated Distribution of Products Sales by Infection Type, 2009
• Table 5-15: World Market for Antiviral Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
• Figure 5-7: World Market for Antiviral Drugs Estimated Revenues of Leading Suppliers 2006-2009
• Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of Leading Suppliers, 2009
• Table 5-16: World Market for Antiviral Drugs Estimated Sales of Top Products 2006-2009
• Figure 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2006-2009

CHAPTER SIX: MARKET SUMMARY

• Table 6-1: The Global Market for Anti-Infectives by ProductSegment, 2006-2013
• Figure 6-1: The World Market for Anti-Infective Drugs 2006-2013
• Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2009
• Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2013